107 SPRING STREET, SEATTLE, WA
Market cap: $92.6M (12/21/2025)
Price: $0.72
Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
Reg. FD
Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces Second Quarter 2025 Financial Results and Provides a Corporate Update
Announces First Quarter 2025 Financial Results and Provides a Corporate Update
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Registration Statement for Additional Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Delisting Amendment
Correspondence
Submission Upload